COVID19. disease diagnosis of COVID-19 confirmed by laboratory testing.
Conditions
Interventions
Intervention 1: Intervention group: Tab Thalidomide ( Talidex) from Alan pharmaceuticals, daily until 14 days. Both case and control group will be received hydroxychloroquine tablet 100 mg BD, methylp
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 18-75 year old men and 50-75 year old women admitted in hospital Spo2 less than 85% in admission Clinical symptoms and signs compatible with COVID19 infection and positive PCR test or lung HRCT abnormalities compatible with COVID19 pneumonia No need to intubation in first 24 hour of admission No multiorgan failure at presentation No shock state at presentation Obtained informed consent
Exclusion criteria
Exclusion criteria: Hepatic failure (Child Pugh score = C, AST> 5 times of the upper limit normal) Severe renal dysfunction (GFR less than 30cc per min)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of Thalidomide in severe Covid19 pneumonia. Timepoint: Daily until discharge and then weekly until 28 days. Method of measurement: history, pulse oximetry, sphygmomanometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| 28 days survival rate. Timepoint: daily until discharge and then weekly until 28 days. Method of measurement: history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzane Ashrafi
Esfahan University of Medical Sciences
Outcome results
None listed